中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

质子泵抑制剂在慢加急性肝衰竭治疗中的应用

姚俞昊 夏潇 张嘉鑫 李小科 叶永安

引用本文:
Citation:

质子泵抑制剂在慢加急性肝衰竭治疗中的应用

DOI: 10.3969/j.issn.1001-5256.2022.12.035
基金项目: 

国家自然科学基金 82174341;

国家中医药管理局科研基金 JDZX2015300;

北京中医药大学重点攻关项目 2022-JYB-ZDGG-115

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:叶永安、李小科对研究思路、设计有关键贡献;姚俞昊、夏潇参与了研究数据的获取分析解释过程;姚俞昊起草论文;李小科、张嘉鑫对文章关键内容进行了修改。
详细信息
    通信作者:

    李小科,lixiaoke@vip.163.com

    叶永安,yeyongan@vip.163.com

Application of proton pump inhibitors in acute-on-chronic liver failure

Research funding: 

National Natural Science Foundation of China 82174341;

Scientific Research Projects of National Administration of Traditional Chinese Medicine JDZX2015300;

Major Research Project of Beijing University of Chinese Medicine 2022-JYB-ZDGG-115

More Information
  • 摘要: 质子泵抑制剂(PPI)是临床常用药物,目前在慢加急性肝衰竭人群中广泛应用。然而这一用药现状未得到美国胃肠病学会最新慢加急性肝衰竭临床指南推荐支持。笔者结合国内外指南或共识,综合最新研究进展,以评述PPI在慢加急性肝衰竭人群中的使用指征、可能获益及潜在风险,以期为临床慢加急性肝衰竭人群规范使用PPI提供参考。

     

  • 表  1  国内外肝衰竭指南对PPI应用的推荐意见

    Table  1.   Recommendations for PPI indications in domestic and international liver failure guidelines

    项目 ACG指南[6] 我国指南[11] EASL指南[12]
    推荐意见 (1)除非有明确适应证,避免使用PPI,因为会增加感染的风险。
    (2)机械通气的人群可使用PPI预防应激性溃疡。
    预防性使用H2受体阻滞剂或PPI (1)使用时应注意感染的风险。
    (2)肠内营养建立时应考虑停用PPI。
    证据依据人群 意见1:肝硬化意见2:ICU人群 消化性溃疡出血 非肝病人群
    下载: 导出CSV
  • [1] National Health Commission of the People's Republic of China. Guidelines for the clinical use of proton pump inhibitors (2020 Edition)[J]. Chin Pract J Rural Doctor, 2021, 28(1): 1-9. DOI: 10.3969/j.issn.1672-7185.2021.01.001.

    中华人民共和国国家卫生健康委员会. 质子泵抑制剂临床应用指导原则(2020年版)[J]. 中国实用乡村医生杂志, 2021, 28(1): 1-9. DOI: 10.3969/j.issn.1672-7185.2021.01.001.
    [2] ZHANG M, XU X, LIU W, et al. Proton pump inhibitor therapy increases the risk of spontaneous bacterial peritonitis in patients with HBV-related acute-on-chronic liver failure[J]. Adv Ther, 2021, 38(9): 4675-4694. DOI: 10.1007/s12325-021-01844-1.
    [3] BIAN M, CHEN SM, SHI WZ, et al. Analysis and investigation in the current situation of using proton pump inhibitor in intensive care unit in six cities in China from 2014 to 2020[J]. Clin Med J, 2022, 20(2): 32-38. DOI: 10.3969/j.issn.1672-3384.2022.02.007.

    边萌, 陈淑敏, 史卫忠, 等. 2014—2020年我国六城市重症医学科质子泵抑制剂用药现状调查与分析[J]. 临床药物治疗杂志, 2022, 20(2): 32-38. DOI: 10.3969/j.issn.1672-3384.2022.02.007.
    [4] SUN S, YE W, ZHAO R, et al. Proton pump inhibitor therapy does not affect prognosis of cirrhosis patients with acute decompensation and acute-on-chronic liver failure: A Single-center prospective study[J]. Front Med (Lausanne), 2021, 8: 763370. DOI: 10.3389/fmed.2021.763370.
    [5] LIN ZN, ZUO YQ, HU P. Association of proton pump inhibitor therapy with hepatic encephalopathy in hepatitis B virus-related acute-on-chronic liver failure[J]. Hepat Mon, 2014, 14(4): e16258. DOI: 10.5812/hepatmon.16258.
    [6] BAJAJ JS, O'LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. DOI: 10.14309/ajg.0000000000001595.
    [7] SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [8] MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022, 71(1): 148-155. DOI: 10.1136/gutjnl-2020-322161.
    [9] AL-MAHTAB M, AKBAR SM, GARG H. Influence of variceal bleeding on natural history of ACLF and management options[J]. Hepatol Int, 2016, 10(3): 436-439. DOI: 10.1007/s12072-015-9677-2.
    [10] ZHAO H, ZHAO R, HU J, et al. Upper gastrointestinal hemorrhage in acute-on-chronic liver failure: prevalence, characteristics, and impact on prognosis[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(3): 263-269. DOI: 10.1080/17474124.2019.1567329.
    [11] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [12] European Association for the Study of the Liver, Clinical practice guidelines panel, WENDON J, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66(5): 1047-1081. DOI: 10.1016/j.jhep.2016.12.003.
    [13] 任红主译. SCHIFF肝脏病学[M]. 北京: 中国科学技术出版社, 2021.

    REN H. Schiff's Diseases of the liver, 12e[M]. Beijing: China Science And Technology Press, 2021.
    [14] Beijing Society of Portal Hypertension, Portal Hypertension Expert Committee, Liver Disease Committee of Chinese Research Hospital Association. Expert consensus on multidisciplinary diagnosis and treatment of cirrhotic portal hypertension (based on hepatic venous pressure gradient)[J]. J Clin Hepatol, 2021, 37(9): 2037-2044. DOI: 10.3969/j.issn.1001-5256.2021.09.008.

    北京医师协会门静脉高压专科医师分会, 中国研究型医院学会肝病专业委员会门静脉高压学组, 中国研究型医院学会肝病专业委员会. 肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识[J]. 临床肝胆病杂志, 2021, 37(9): 2037-2044. DOI: 10.3969/j.issn.1001-5256.2021.09.008.
    [15] Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Endoscopy. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
    [16] DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [17] PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group, Young PJ, Bagshaw SM, et al. Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among icu patients receiving invasive mechanical ventilation: The PEPTIC randomized clinical trial[J]. JAMA, 2020, 323(7): 616-626. DOI: 10.1001/jama.2019.22190.
    [18] ALSHAMSI F, BELLEY-COTE E, COOK D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials[J]. Crit Care, 2016, 20(1): 120. DOI: 10.1186/s13054-016-1305-6.
    [19] SREEDHARAN A, MARTIN J, LEONTIADIS GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding[J]. Cochrane Database Syst Rev, 2010, (7): CD005415. DOI: 10.1002/14651858.CD005415.pub3.
    [20] CHEN CL, MAO H, TANG YL, et al. Effective assessment of PPI in cirrhotic patients[J]. Chin J Gastroenterol Hepatol, 2012, 21(3): 250-252. DOI: 10.3969/j.issn.1006-5709.2012.03.016.

    陈春林, 毛华, 唐银丽, 等. 质子泵抑制剂用于肝硬化患者的疗效评估[J]. 胃肠病学和肝病学杂志, 2012, 21(3): 250-252. DOI: 10.3969/j.issn.1006-5709.2012.03.016.
    [21] NAKATAKE R, HISHIKAWA H, KOTSUKA M, et al. The proton pump inhibitor lansoprazole has hepatoprotective effects in in vitro and in vivo rat models of acute liver injury[J]. Dig Dis Sci, 2019, 64(10): 2854-2866. DOI: 10.1007/s10620-019-05622-6.
    [22] NISHI T, YAMAMOTO Y, YAMAGISHI N, et al. Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats[J]. J Pharm Pharmacol, 2018, 70(3): 383-392. DOI: 10.1111/jphp.12870.
    [23] ELTAHIR HM, NAZMY MH. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers[J]. Biomed Pharmacother, 2018, 97: 1356-1365. DOI: 10.1016/j.biopha.2017.11.028.
    [24] AL-HADRAWY S, MAHDI AL-TURFI ZS. Effects of the long-term treatment of proton pump inhibitors on the function of kidney and liver in laboratory female rats[J]. Arch Razi Inst, 2021, 76(4): 975-983. DOI: 10.22092/ari.2021.355947.1745.
    [25] ATKINS C, MAHESWARAN T, RUSHBROOK S, et al. Lansoprazole-induced acute lung and liver injury: a case report[J]. Int J Clin Pharmacol Ther, 2014, 52(12): 1102-1104. DOI: 10.5414/CP202110.
    [26] GARCÍA-CORTÉS M, LUCENA MI, ANDRADE RJ, et al. Lansoprazole-induced hepatic dysfunction[J]. Ann Pharmacother, 2003, 37(11): 1731. DOI: 10.1345/aph.1C268.
    [27] THOMAS B, MOHAMED M, AL HAIL M, et al. A case of probable esomeprazole-induced transient liver injury in a pregnant woman with hyperemesis[J]. Clin Pharmacol, 2016, 8: 199-202. DOI: 10.2147/CPAA.S106234.
    [28] ROGALSKI P, ZABOROWSKA M, MAZUR M, et al. Gastrointestinal hemorrhage as an acute-on-chronic liver failure trigger in cirrhotic patients[J]. Adv Clin Exp Med, 2022. DOI: 10.17219/acem/147464.
    [29] LO EA, WILBY KJ, ENSOM MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review[J]. Ann Pharmacother, 2015, 49(2): 207-219. DOI: 10.1177/1060028014559244.
    [30] GARCIA-SAENZ-DE-SICILIA M, SANCHEZ-AVILA F, CHAVEZ-TAPIA NC, et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis[J]. World J Gastroenterol, 2010, 16(46): 5869-5873. DOI: 10.3748/wjg.v16.i46.5869.
    [31] BAJAJ JS, ZADVORNOVA Y, HEUMAN DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites[J]. Am J Gastroenterol, 2009, 104(5): 1130-1134. DOI: 10.1038/ajg.2009.80.
    [32] JANKA T, TORNAI T, BORBÉLY B, et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis[J]. Eur J Gastroenterol Hepatol, 2020, 32(2): 257-264. DOI: 10.1097/MEG.0000000000001499.
    [33] KWON JH, KOH SJ, KIM W, et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis[J]. J Gastroenterol Hepatol, 2014, 29(4): 775-781. DOI: 10.1111/jgh.12426.
    [34] SHALIMAR, ROUT G, JADAUN SS, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients[J]. Dig Liver Dis, 2018, 50(11): 1225-1231. DOI: 10.1016/j.dld.2018.05.013.
    [35] LIN ZN, ZUO YQ, ZHOU Z, et al. Association of proton pump inhibitor therapy with hepatic encephalopathy in acute-on-chronic liver failure[C]//Proceedings of the 16th National Conference on hepatitis and liver diseases of the Chinese Medical Association. 2013: 413-414.

    蔺朝妮, 左永清, 周智, 等. 慢加急性肝衰竭患者质子泵抑制剂的应用与肝性脑病的关系[C]//中华医学会第十六次全国病毒性肝炎及肝病学术会议论文集. 2013: 413-414.
    [36] de ROZA MA, KAI L, KAM JW, et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis[J]. World J Gastroenterol, 2019, 25(33): 4933-4944. DOI: 10.3748/wjg.v25.i33.4933.
  • 加载中
表(1)
计量
  • 文章访问数:  1270
  • HTML全文浏览量:  904
  • PDF下载量:  91
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-20
  • 录用日期:  2022-05-24
  • 出版日期:  2022-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回